Advances in targeted therapies XIII

Preface

i1 Advances in targeted therapies XIII  
FC Breedveld, JR Kalden, JS Smolen

Consensus statement

i2 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011  

Papers

i46 HDAC inhibitor therapy in autoimmunity and transplantation  
W W Hancock, T Akimova, U H Beier, Y Liu, L Wang

i55 TNF and EPO: major players in the innate immune response: their discovery  
A Crema

i60 Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats  
C Bogdan

i67 How do contemporary imaging techniques contribute to basic and clinical rheumatology?  
M Ishii

i70 In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis  
Y Tanaka, Y Maeshima, K Yamazaki

i75 Antiensense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis  
S Yilmaz-Ebih, A Arinta-Rou, A Vosse, J van Deenen, S de Kampe, P A C de Heen, C J van Ommen, J S Verbeek

i78 CD23 defects in systemic lupus erythematosus  
T Takeuchi, K Suzuki, T Konno, K Yoshimoto, K Osanaka

i82 New approaches to the assessment and treatment of the idiopathic inflammatory myopathies  
P W Miller

i86 Defining remission in rheumatoid arthritis  
D Felson

i89 Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?  
D van der Heijde

i93 How to define remission in ankylosing spondylitis?  
J Sieper

i96 Roles of LAG3 and EGR2 in regulatory T cells  
T Okumura, K Fujio, S Sumimoto, K Yamamoto

i101 IL-33: a Janus cytokine  
F Y Liew